



Novartis India Limited
Registered Office:
Inspire BKC
7th Floor
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.com

May 14, 2024

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Scrip Code: 500672

Dear Sir/ Madam,

Sub: Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find enclosed intimation dated May 13, 2024 received from Link Intime India Private Limited, Registrar and Transfer Agent, providing information regarding issue of duplicate share certificate in favour of shareholder of the Company.

Further, in accordance with the SEBI Notification No. SEBI/LAD-NRO/GN/2022/66 dated January 24, 2022, read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, letter of confirmation in lieu of the physical share certificate will be issued to the said shareholder of the Company within the prescribed timelines.

Request you to kindly take the same on record.

Thanking you,

Yours Sincerely,

For Novartis India Limited

Joshi
Shilpa

Digitally signed by
Joshi Shilpa
Date: 2024.05.14
13:54:16 +05'30'

Shilpa Joshi
Whole-Time Director and Chief Financial Officer

Encl: as above



Date: 13.05.2024

To,
Company Secretary
Novartis India Limited

Sub: Regulation 39(3) of SEBI (LODR), 2015.

Dear Sir / Madam,

Please find below mentioned details pertaining to the security for which Duplicate Certificate has been issued considering approval date 13.05.2024.

Sl. No.	Shareholder(s) Name	Folio No.	New Certificate No.	No. of Shares	Distinctive nos.
1	AJIT MAHADEO AGHARKAR	01004883	442517	66	29770 - 29835

Yours Faithfully,
Link Intime India Private Limited


Authorized Signatory